The product is being distributed by Mylan Pharmaceuticals. Valacyclovir Hydrochloride Tablets had US sales of approximately $2.15 billion for the 12 months ending ending March 31, 2010, according to IMS Health.

Currently, Mylan has 142 ANDAs pending FDA approval representing $95.6 billion in annual brand sales. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.6 billion in annual brand sales for the 12 months ending December 31, 2009, according to IMS Health.

Will Matrix benefit with the approval?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.